Enzo Biochem Inc. announced on Tuesday that it was issued aU.S. patent, No. 5,190,931, involving genetic antisensetechnology. Enzo said it plans to use its technology to developits own proprietary products, largely in the field of humantherapeutics and plants, and to sublicense others as well asengage in joint ventures.
Enzo received a notice of allowance for the patent last August.
In February, Calgene Inc. (NASDAQ:CGNE) of Davis, Calif.,developer of Flavr Savr tomatoes, sued Enzo (ASE:ENZ) ofFarmingdale, N.Y., to invalidate Enzo's then-pending patent andobtain damages.
(c) 1997 American Health Consultants. All rights reserved.